<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kaushal JB</submitter><funding>United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs</funding><funding>United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (CDMRP)</funding><pagination>1007-1023</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11976299</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>44(15)</volume><pubmed_abstract>The functional activation of the androgen receptor (AR) and its interplay with the aberrant Hh/Gli cascade are pivotal in the progression of castration-resistant prostate cancer (CRPC) and resistance to AR-targeted therapies. Our study unveiled a novel role of the truncated form of Gli (t-Gli3) in advancing CRPC. Investigation into Gli3 regulation revealed a Smo-independent mechanism for its activation. Despite lacking a transactivation domain, t-Gli3 relies on androgen receptor variant 7 (AR-V7) for its action. Mechanistically, Gsk3β activation led to the t-Gli3 generation, and inhibition of Gsk3β supported the accumulation of full-length Gli3 expression through a non-canonical mechanism. Knockdown of Gsk3β (Gsk3β KD) reduces CRPC cell proliferation, induces apoptosis via mitochondrial fr</pubmed_abstract><journal>Oncogene</journal><pubmed_title>Oncogenic potential of truncated-Gli3 via the Gsk3β/Gli3/AR-V7 axis in castration-resistant prostate cancer.</pubmed_title><pmcid>PMC11976299</pmcid><funding_grant_id>DOD W81XWH-18-1-0308</funding_grant_id><funding_grant_id>DOD W81XWH-21-1-0340</funding_grant_id><funding_grant_id>W81XWH-21-1-0640</funding_grant_id><pubmed_authors>Parte S</pubmed_authors><pubmed_authors>Kaushal JB</pubmed_authors><pubmed_authors>Raut P</pubmed_authors><pubmed_authors>Sharma G</pubmed_authors><pubmed_authors>Seshacharyulu P</pubmed_authors><pubmed_authors>Lele SM</pubmed_authors><pubmed_authors>Batra SK</pubmed_authors><pubmed_authors>Halder S</pubmed_authors><pubmed_authors>Siddiqui JA</pubmed_authors><pubmed_authors>Alsafwani ZW</pubmed_authors><pubmed_authors>Abdullah KM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Oncogenic potential of truncated-Gli3 via the Gsk3β/Gli3/AR-V7 axis in castration-resistant prostate cancer.</name><description>The functional activation of the androgen receptor (AR) and its interplay with the aberrant Hh/Gli cascade are pivotal in the progression of castration-resistant prostate cancer (CRPC) and resistance to AR-targeted therapies. Our study unveiled a novel role of the truncated form of Gli (t-Gli3) in advancing CRPC. Investigation into Gli3 regulation revealed a Smo-independent mechanism for its activation. Despite lacking a transactivation domain, t-Gli3 relies on androgen receptor variant 7 (AR-V7) for its action. Mechanistically, Gsk3β activation led to the t-Gli3 generation, and inhibition of Gsk3β supported the accumulation of full-length Gli3 expression through a non-canonical mechanism. Knockdown of Gsk3β (Gsk3β KD) reduces CRPC cell proliferation, induces apoptosis via mitochondrial fr</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Apr</publication><modification>2025-07-05T03:04:32.151Z</modification><creation>2025-07-05T03:04:32.151Z</creation></dates><accession>S-EPMC11976299</accession><cross_references><pubmed>39821099</pubmed><doi>10.1038/s41388-024-03266-z</doi></cross_references></HashMap>